title: Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin.
abstract: Recently, in rat abdominal aorta terminoterminal-anastomosis the stable gastric pentadecapeptide BPC 157 prevents obstructive thrombus formation and rapidly destroys already formed obstructive thrombus. Also, BPC 157 wound healing may signify the clot as conductive matrix or "scaffold" to speed up wound healing process, and decrease bleeding. Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg, 25mg/kg, 10mg/kg i.v.), warfarin (1.5mg/kg i.g. once daily for 3 consecutive days), aspirin (0.1g/kg i.g. (once daily/3 consecutive days) or 1.0 g/kg i.p. once), and amputation associated with those agents application. BPC 157 counteracting regimens (i.v., i.p., i.g. (immediately after any challenge)) correspondingly follow the route of bleeding-agents application. All heparin-, warfarin-, and aspirin-rats and normal-rats that received BPC 157 exhibited lesser fall in platelets count. BPC 157 attenuated over-increased APTT-, TT-values in 10mg/kg heparin-rats, but did not influence heparin activity (anti-Xa test). Indicatively, unless counteracted in BPC 157 rats, excessive bleeding-acute thrombocytopenia (<20% of initial values in heparin-rats) approaches substantial fall in platelets count known in type II HIT. Also, BPC 157 markedly prolongs the survival time (heparin-rats, 25mg/kg, right foot amputation).
authors.affiliation: Department of Pharmacology and Pathology Medical Faculty University of Zagreb, Zagreb, Croatia.
authors.forename: Mirjana
authors.initials: M
authors.lastname: Stupnisek
authors.forename: Sandra
authors.initials: S
authors.lastname: Franjic
authors.forename: Domagoj
authors.initials: D
authors.lastname: Drmic
authors.forename: Masa
authors.initials: M
authors.lastname: Hrelec
authors.forename: Danijela
authors.initials: D
authors.lastname: Kolenc
authors.forename: Bozo
authors.initials: B
authors.lastname: Radic
authors.forename: Davor
authors.initials: D
authors.lastname: Bojic
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Vcev
authors.forename: Sven
authors.initials: S
authors.lastname: Seiwerth
authors.forename: Predrag
authors.initials: P
authors.lastname: Sikiric
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology*; D001760:Bleeding Time; D006493:Heparin / Q000494:pharmacology*; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013921:Thrombocytopenia / Q000097:blood* / Q000188:drug therapy*; D014859:Warfarin / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; D014859:Warfarin; C083833:BPC 157; D006493:Heparin; D001241:Aspirin